Guidant Comments on the Status of its ACTION Drug Eluting Stent Trial.
Business Editors & Health/Medical Writers
INDIANAPOLIS--(BW HealthWire)--Feb. 22, 2002
Guidant Corporation (NYSE NYSE
See: New York Stock Exchange :GDT GDT Global Descriptor Table
GDT Geographic Data Technology Inc.
GDT Gas Discharge Tube (energy, electrotechinical and electronics)
GDT Getting Things Done
GDT Geometric Dimensioning & Tolerancing
GDT Ground Data Terminal )(PCX (1) A bitmapped graphics file format that handles monochrome, 2-bit, 4-bit, 8-bit and 24-bit color and uses RLE to achieve compression ratios of approximately 1.1:1 to 1.5:1. Images with large blocks of solid colors compress best under the RLE method. See PC Paintbrush. :GDT), a global leader in cardiac and vascular technology, today issued the following statement on the status of its international ACTION clinical trial evaluating its drug eluting stent system utilizing Actinomycin D actinomycin D Cosmegen®, dactinomycin Oncology A relatively toxic antibiotic produced by Streptomyces spp, used as a chemotherapeutic Mechanism Inhibits DNA transcription by RNA polymerase Indications Rhabdomyosarcoma, Wilms' tumor Adverse . The company is issuing this statement in response to speculation on the trial based on anecdotal data.
Guidant is now in the six-month follow-up phase of the ACTION trial, having completed enrollment in November. Thirty-day follow-up has revealed no safety concerns. The results of the trial are blinded and the data is currently being collected for evaluation. Consequently, the company will not comment on anecdotal data or speculation relating to the trial.
Guidant is looking forward to its first opportunity to report on the full 360 patient ACTION data set at the Paris Course (cardiology medical conference) in late May.
The ACTION Trial is evaluating Guidant's internal drug eluting stent program utilizing Actinomycin-D in patients with de novo [Latin, Anew.] A second time; afresh. A trial or a hearing that is ordered by an appellate court that has reviewed the record of a hearing in a lower court and sent the matter back to the original court for a new trial, as if it had not been previously heard nor decided. lesions in native coronary arteries Coronary arteries
The two main arteries that provide blood to the heart. The coronary arteries surround the heart like a crown, coming out of the aorta, arching down over the top of the heart, and dividing into two branches. . The trial enrolled the 360 patients at 28 centers primarily in Europe.
Guidant is advancing multiple drug eluting stent programs and is well on its way toward providing customers with the broadest and deepest drug eluting stent product line in the industry, the company stated.
Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to 7 million cardiac and vascular patients worldwide. The company, driven by a strong entrepreneurial culture of 10,000 employees, develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life's most threatening medical conditions. For more information visit www.guidant.com.